Study finds convincing evidence that the combined oral contraceptive pill helps painful periods

18 January 2012

A large Scandinavian study that has been running for 30 years has finally provided convincing evidence that the combined oral contraceptive pill does, indeed, alleviate the symptoms of painful menstrual periods โ€“ dysmenorrhoea. The research is published online in Europeโ€™s leading reproductive medicine journal Human Reproduction [1] today (Wednesday).

FoR Press banner HR_HR Press 2012

Although some previous studies and anecdotal evidence have suggested that the combined oral contraceptive pill could have an impact on painful periods, a 2009 review of all the available research by the prestigious Cochrane Collaboration concluded that there was limited evidence for pain improvement.

The new findings by Dr Ingela Lindh and her colleagues at the Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Sweden, show that women who used the combined oral contraceptive pill suffered less severe pain compared with women who did not use it. Young women often seem to suffer more from painful periods than older women, and the researchers also found that increasing age did alleviate the symptoms, but the effects of pill use and age were independent of each other, with the pill having a greater effect.

The researchers questioned three groups of women who reached the age of 19 in 1981, 1991 and 2001. Each group included approximately 400 to 520 women, who provided information on their height, weight, reproductive history, pattern of menstruation and menstrual pain, and contraceptive use. Five years later they were assessed again at the age of 24.

By comparing the same women at two different ages, the researchers were able to use each woman as her own control, enabling them to establish whether any reduction in severity of symptoms was due to combined oral contraceptive (COC) use or increasing age.

Dr Lindh, who is also a registered nurse and midwife, said: โ€œBy comparing women at different ages, it was possible to demonstrate the influence of COCs on the occurrence and severity of dysmenorrhoea, at the same time taking into account possible changes due to increasing age. We found there was a significant difference in the severity of dysmenorrhoea depending on whether or not the women used combined oral contraceptives.โ€

Pain and other symptoms were measured by two different scales: VMS (verbal multidimensional scoring system), which grades pain as none, mild, moderate or severe, and also takes into account the effect on daily activity and whether any painkillers were required; and VAS (visual analogue scale), where a woman can grade her degree of pain on a 10 cm line that starts with โ€œno pain at allโ€ and ends with โ€œunbearable painโ€.

Dr Lindh said: โ€œWe found that combined oral contraceptive use reduced dysmenorrhoea by 0.3 units, which means that every third woman went one step down on the VMS scale, for instance from severe pain to moderate pain, and which meant that they suffered less pain, improved their working ability and there was a decrease in the need for analgesics. On the VAS scale there was a reduction in pain of nine millimetres.โ€

Independent of the effect of COC use, the researchers found that increasing age reduced the severity of dysmenorrhoea but not as much as COC did; it shifted women down 0.1 units on the VMS scale and five millimetres on the VAS scale. Childbirth also seemed to reduce the severity of symptoms, but this result was limited by the fact that very few women had given birth between the ages of 19 and 24.

The researchers also found that in the youngest group (those born in 1982), more women reported suffering from painful periods, and the severity of the symptoms was worse.

โ€œWe are unsure why this is,โ€ said Dr Lindh. โ€œIt may be due to changes in the type of oral contraceptive used, for example, differences in oestrogen content and progestogen type, or a different appreciation of pain in the women born in later years, in that they may be more pain sensitive or are more prepared to complain about pain than women of the same age but born earlier.โ€

Dysmenorrhoea has been estimated to account for 600 million lost working hours and two billion dollars in lost productivity in the USA. Dr Lindh said: โ€œPainful periods occurs frequently, particularly in young women where as many as 50-75% suffer from dysmenorrhoea. It can have a detrimental effect on these womenโ€™s lives, causing regular absenteeism from school and work, and interfering with their daily activities for several days each month. Therefore effective management of dysmenorrhoea is beneficial for both the women affected and society.

โ€œInformation about the effects of COC use on painful periods should be included in contraceptive counselling, as it has been shown that women who experience a beneficial effect of COCs other than contraception, such as a reduction in dysmenorrhoea, are more likely to continue with the pill.โ€

At present, the combined oral contraceptive pill is approved for contraception by regulatory authorities such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), and they would require a randomised controlled trial to in order to include dysmenorrhoea treatment as another indication for COC use, although some doctors already prescribe it โ€œoff-labelโ€ to help with painful periods.

Dr Lindh said: โ€œWe are aware that drug companies have discussed with the authorities the possible design of a randomised controlled trial for the evaluation of COCs in the treatment of dysmenorrhoea but this has not yet been finalised or performed. However, our study has clearly indicated a beneficial influence of COCs on the prevalence and severity of dysmenorrhoea and the absence of a randomised controlled trial confirming this in no way reduces the value of this information.โ€ 

[1] โ€œThe effect of combined oral contraceptives and age on dysmenorrhoea: an epidemiological studyโ€, by Ingela Lindh, Agneta Andersson Ellstrรถm, and Ian Milsom. Human Reproduction journal. doi:10.1093/humrep/der417

Human Reproduction is a monthly journal of the European Society of Human Reproduction and Embryology (ESHRE), and is published by Oxford Journals, a division of Oxford University Press.
Please acknowledge Human Reproduction as a source in any articles.
ESHREโ€™s website is: www.eshre.eu

Abstracts of other papers in ESHREโ€™s three journals โ€“ Human Reproduction, Molecular Human Reproduction and Human Reproduction Update โ€“ can be accessed post embargo from: http://humrep.oxfordjournals.org/
http://humupd.oxfordjournals.org/
http://molehr.oxfordjournals.org/
Papers are available on request from Emma Mason.

Contact (media enquiries only):
Emma Mason
Mobile: +44 (0)7711 296 986
Email: wordmason@mac.com
Skype: Jemmam12

Related items

Human Reproduction

Better semen quality is linked to men living longer

Embargoed: 00.05 hrs GMT, Wednesday 5 March 2025

Menโ€™s semen quality is associated with how long they live according to a study of nearly 80,000 men, which is published today (Wednesday) in Human Reprodu...
Read here
Human Reproduction

Women with premature ovarian insufficiency are at greater risk of severe autoimmune diseases

Embargoed: 00.05 hrs British Summer Time, Thursday 26 September 2024

Severe autoimmune conditions such Type I diabetes, Addisonโ€™s disease, lupus and inflammatory bowel disease, are between two to three t...
Read here
Human Reproduction

Evidence-based information combats misleading and false claims on the internet and social media about the anti-Mullerian hormone test

Embargoed: 00.05 hrs British Summer Time, Monday 29 July 2024

Researchers in Australia have found that when women are given accurate information about a test that indicates the number of eggs in their ov...
Read here

Register to our Annual Meeting

Participate in the greatest event in reproductive science and medicine.

Register